ArticleActa odontologica Scandinavica2025
Effect of resveratrol on the antioxidant enzyme pathway and alveolar bone loss in experimental periodontitis.
Article in Acta odontologica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salivary glutathione peroxidase-1 levels in periodontitis.World journal of methodology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to investigate the effect of resveratrol in a rat model of experimental periodontitis by assessing alveolar bone loss along with catalase and glutathione peroxidase mRNA expression and enzymatic activity in gingival tissue. MATERIAL AND
methodsExperimental periodontitis was induced in 34 male Sprague-Dawley rats by placing silk ligatures bilaterally around mandibular first molars. Then the animals were randomly divided into two groups: placebo (n = 17) and resveratrol (n = 17). The placebo group received a placebo solution, while the resveratrol group received 10 mg/kg resveratrol daily via oral gavage for 30 days. Alveolar bone loss was measured on microscopic photographs of stained tissue sections. Gingival enzyme activity levels were determined by enzyme-specific reactions and mRNA levels were assessed using semiquantitative real-time polymerase chain reaction (PCR).
resultsSystemic resveratrol administration significantly reduced alveolar bone loss (440.87 ± 142.24 μm) compared to the placebo group (897.06 ± 383.59 μm) (p < 0.001). Catalase and glutathione peroxidase activities were also significantly higher in the resveratrol group (p < 0.001).
conclusionsResveratrol appears to be effective in reducing alveolar bone loss in experimental periodontitis, potentially through its antioxidant properties. These findings suggest that resveratrol may offer clinical benefit as an adjunct to periodontal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.